5.80
0.19 (3.39%)
| Previous Close | 5.61 |
| Open | 5.95 |
| Volume | 65,637 |
| Avg. Volume (3M) | 261,846 |
| Market Cap | 208,450,848 |
| Price / Sales | 73.58 |
| Price / Book | 63.33 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,585.09% |
| Diluted EPS (TTM) | -1.98 |
| Quarterly Revenue Growth (YOY) | -9.50% |
| Total Debt/Equity (MRQ) | 58.68% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -69.19 M |
| Levered Free Cash Flow (TTM) | -40.90 M |
| Return on Assets (TTM) | -195.55% |
| Return on Equity (TTM) | -697.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Anteris Technologies Global Cor | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -1.00 |
|
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 7.55% |
| % Held by Institutions | 22.01% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Barclays, 279.31%) | Buy |
| Median | 15.50 (167.24%) | |
| Low | 9.00 (Cantor Fitzgerald, 55.17%) | Buy |
| Average | 15.50 (167.24%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 5.80 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 07 Jan 2025 | 22.00 (279.31%) | Buy | 5.80 |
| Cantor Fitzgerald | 07 Jan 2025 | 9.00 (55.17%) | Buy | 5.80 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Dec 2024 | Announcement | Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |